Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

Prognostic improvement of patients with advanced liver cancer after active hexose correlated compound (AHCC) treatment.

Cowawintaweewat S, Manoromana S, Sriplung H, Khuhaprema T, Tongtawe P, Tapchaisri P, Chaicumpa W.

Asian Pac J Allergy Immunol. 2006 Mar;24(1):33-45.

2.

Improved prognosis of postoperative hepatocellular carcinoma patients when treated with functional foods: a prospective cohort study.

Matsui Y, Uhara J, Satoi S, Kaibori M, Yamada H, Kitade H, Imamura A, Takai S, Kawaguchi Y, Kwon AH, Kamiyama Y.

J Hepatol. 2002 Jul;37(1):78-86.

PMID:
12076865
3.

The influence of active hexose correlated compound (AHCC) on cisplatin-evoked chemotherapeutic and side effects in tumor-bearing mice.

Hirose A, Sato E, Fujii H, Sun B, Nishioka H, Aruoma OI.

Toxicol Appl Pharmacol. 2007 Jul 15;222(2):152-8. Epub 2007 Apr 20.

PMID:
17555784
4.

Alleviating Effect of Active Hexose Correlated Compound (AHCC) on Chemotherapy-Related Adverse Events in Patients with Unresectable Pancreatic Ductal Adenocarcinoma.

Yanagimoto H, Satoi S, Yamamoto T, Hirooka S, Yamaki S, Kotsuka M, Ryota H, Michiura T, Inoue K, Matsui Y, Tsuta K, Kon M.

Nutr Cancer. 2016;68(2):234-40. doi: 10.1080/01635581.2016.1134597. Epub 2016 Feb 4.

PMID:
26847832
5.

Sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombus.

Nagai H, Mukozu T, Ogino YU, Matsui D, Matsui T, Wakui N, Momiyama K, Igarashi Y, Sumino Y, Higai K.

Anticancer Res. 2015 Apr;35(4):2269-77.

PMID:
25862889
6.

Therapeutic effect of Active Hexose-Correlated Compound (AHCC) combined with CpG-ODN (oligodeoxynucleotide) in B16 melanoma murine model.

Ignacio RM, Kim CS, Kim YD, Lee HM, Qi XF, Kim SK.

Cytokine. 2015 Dec;76(2):131-137. doi: 10.1016/j.cyto.2015.06.002. Epub 2015 Jun 13.

PMID:
26082022
7.

Efficacy of pegylated liposomal doxorubicin in patients with advanced hepatocellular carcinoma.

Lind PA, Naucler G, Holm A, Gubanski M, Svensson C.

Acta Oncol. 2007;46(2):230-3.

PMID:
17453374
8.

Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective comparison with previously known prognostic models.

Baek KK, Kim JH, Uhm JE, Park SH, Lee J, Park JO, Park YS, Kang WK, Lim HY.

Oncology. 2011;80(3-4):167-74. doi: 10.1159/000327591. Epub 2011 Jun 24.

PMID:
21701230
9.

Reduction of adverse effects by a mushroom product, active hexose correlated compound (AHCC) in patients with advanced cancer during chemotherapy--the significance of the levels of HHV-6 DNA in saliva as a surrogate biomarker during chemotherapy.

Ito T, Urushima H, Sakaue M, Yukawa S, Honda H, Hirai K, Igura T, Hayashi N, Maeda K, Kitagawa T, Kondo K.

Nutr Cancer. 2014;66(3):377-82. doi: 10.1080/01635581.2014.884232. Epub 2014 Mar 10.

PMID:
24611562
10.

The impact of patient and tumour baseline characteristics on the overall survival of patients with advanced hepatocellular carcinoma treated with sorafenib.

Wörns MA, Koch S, Niederle IM, Marquardt JU, Nguyen-Tat M, Gamstätter T, Schuchmann M, Schulze-Bergkamen H, Galle PR, Weinmann A.

Dig Liver Dis. 2013 May;45(5):408-13. doi: 10.1016/j.dld.2012.10.010. Epub 2012 Nov 21.

PMID:
23182599
11.

Efficacy and safety of epirubicin and etoposide combination chemotherapy in advanced hepatocellular carcinoma: a retrospective analysis.

Lee JL, Ryu MH, Chang HM, Kim TW, Lee SS, Sym SJ, Kim MK, Kim KM, Lee JS, Kang YK.

J Gastroenterol Hepatol. 2008 May;23(5):811-6. Epub 2007 Nov 6.

PMID:
17995941
12.

Importance of branched-chain amino acids in patients with liver cirrhosis and advanced hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy.

Kanekawa T, Nagai H, Kanayama M, Sumino Y.

Cancer Chemother Pharmacol. 2014 Nov;74(5):899-909. doi: 10.1007/s00280-014-2564-z. Epub 2014 Aug 20.

PMID:
25138286
13.

Clinical study on treatment of primary hepatocellular carcinoma by Shenqi mixture combined with microwave coagulation.

Lin JJ, Jin CN, Zheng ML, Ouyang XN, Zeng JX, Dai XH.

Chin J Integr Med. 2005 Jun;11(2):104-10.

PMID:
16150196
14.

Effect of Active Hexose Correlated Compound (AHCC) in alcohol-induced liver enzyme elevation.

Kim H, Kim JH, Im JA.

J Nutr Sci Vitaminol (Tokyo). 2014;60(5):348-56. doi: 10.3177/jnsv.60.348.

15.

Therapeutic strategy of advanced hepatocellular carcinoma by using combined intra-arterial chemotherapy.

Nagai H, Sumino Y.

Recent Pat Anticancer Drug Discov. 2008 Nov;3(3):220-6. Review.

PMID:
18991790
16.

[Clinical observation of cinobufacini injection used to treat moderate and advanced primary liver cancer].

Chen Z, Zhai XF, Su YH, Wan XY, Li J, Xie JM, Gao B.

Zhong Xi Yi Jie He Xue Bao. 2003 Sep;1(3):184-6. Chinese.

PMID:
15339556
17.

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.

Zhu AX, Park JO, Ryoo BY, Yen CJ, Poon R, Pastorelli D, Blanc JF, Chung HC, Baron AD, Pfiffer TE, Okusaka T, Kubackova K, Trojan J, Sastre J, Chau I, Chang SC, Abada PB, Yang L, Schwartz JD, Kudo M; REACH Trial Investigators.

Lancet Oncol. 2015 Jul;16(7):859-70. doi: 10.1016/S1470-2045(15)00050-9. Epub 2015 Jun 18.

PMID:
26095784
18.

Sorafenib in liver function impaired advanced hepatocellular carcinoma.

Ji YX, Zhang ZF, Lan KT, Nie KK, Geng CX, Liu SC, Zhang L, Zhuang XJ, Zou X, Sun L, Zhang ZC.

Chin Med Sci J. 2014 Mar;29(1):7-14.

PMID:
24698672
19.

Analysis of prognostic factors and 5-year survival rate in patients with hepatocellular carcinoma: a single-center experience.

Lee SS, Shin HS, Kim HJ, Lee SJ, Lee HS, Hyun KH, Kim YH, Kwon BW, Han JH, Choi H, Kim BH, Lee JH, Kang HY, Shin HD, Song IH.

Korean J Hepatol. 2012 Mar;18(1):48-55. doi: 10.3350/kjhep.2012.18.1.48. Epub 2012 Mar 22.

20.

Immunological effect of active hexose correlated compound (AHCC) in healthy volunteers: a double-blind, placebo-controlled trial.

Terakawa N, Matsui Y, Satoi S, Yanagimoto H, Takahashi K, Yamamoto T, Yamao J, Takai S, Kwon AH, Kamiyama Y.

Nutr Cancer. 2008;60(5):643-51. doi: 10.1080/01635580801993280.

PMID:
18791928

Supplemental Content

Support Center